Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01504867 · ClinicalTrials.gov registry record · Phase 2
LIPS-A: Lung Injury Prevention Study With Aspirin
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT01504867: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01504867 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01504867, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.
Interventions
- DRUG Aspirin
- DRUG Lactose powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01504867
The ClinicalTrials.gov registry entry for NCT01504867 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT01504867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01504867 about?
NCT01504867 is a clinical study titled "LIPS-A: Lung Injury Prevention Study With Aspirin". The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.
What is the current status of trial NCT01504867?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2012-01. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01504867?
The interventions under investigation include: Aspirin (DRUG), Lactose powder (DRUG).
Who is sponsoring clinical trial NCT01504867?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.